Ono Pharmaceutical Co., Ltd., along with its affiliated companies, is engaged in the global development, manufacturing, procurement, and sale of a diverse range of pharmaceutical products and diagnostic tools. Its diverse oncology portfolio includes OPDIVO intravenous infusions, KYPROLIS for injection, MEKTOVI, VELEXBRU, and ADLUMIZ tablets, along with BRAFTOVI capsules, all prescribed for various malignant tumors. It also provides EMEND capsules and PROEMEND intravenous injections to alleviate chemotherapy-induced nausea and vomiting, and DEMSER capsules for managing symptoms in pheochromocytoma patients. Beyond oncology, the company's offerings span multiple therapeutic areas. For metabolic disorders, it supplies GLACTIV and FORXIGA tablets for type 2 diabetes. Cardiovascular health is supported by ONOACT injections for tachyarrhythmia, CORALAN for chronic heart failure, and OPALMON tablets addressing peripheral circulatory disorders. Autoimmune conditions like rheumatoid arthritis are treated with ORENCIA injections. Neurological therapies include RIVASTACH patches for Alzheimer's disease and ONGENTYS tablets for Parkinson's disease. Other notable products are PARSABIV intravenous injections for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, and RECALBON tablets for osteoporosis, with JOYCLU intra-articular injection available to improve joint function. Moreover, the company is heavily invested in research and development, with a pipeline targeting a wide array of diseases. This includes various malignancies such as esophageal, urothelial, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular, pancreatic, biliary tract, gastric, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, and virus-positive/negative solid tumors, as well as primary central nervous system lymphoma. Beyond cancer, its developmental efforts extend to myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative and autoimmune disorders, narcolepsy, and thrombosis. Established in 1717, the company maintains its corporate headquarters in Osaka, Japan.
The current price of OPHLF is $14.90 USD — it has increased by +5.67% in the past 24 hours. Watch Ono Pharmaceutical stock price performance more closely on the chart.
What is Ono Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Ono Pharmaceutical stocks are traded under the ticker OPHLF.
Is Ono Pharmaceutical stock price growing?▼
OPHLF stock has risen by +0% compared to the previous week, the month change is a -2.61% fall, over the last year Ono Pharmaceutical has showed a +21.93% increase.
What is Ono Pharmaceutical market cap?▼
Today Ono Pharmaceutical has the market capitalization of 7.43B
When is the next Ono Pharmaceutical earnings date?▼
Ono Pharmaceutical is going to release the next earnings report on February 1, 2027.
What were Ono Pharmaceutical earnings last quarter?▼
OPHLF earnings for the last quarter are 0.28 USD per share, whereas the estimation was 0.28 USD resulting in a +1.6% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ono Pharmaceutical revenue for the last year?▼
Ono Pharmaceutical revenue for the last year amounts to 3.4B USD.
What is Ono Pharmaceutical net income for the last year?▼
OPHLF net income for the last year is 462.91M USD.
Does Ono Pharmaceutical pay dividends?▼
Yes, OPHLF dividends are paid semi-annual. The last dividend per share was 0.25 . As of today, Dividend Yield (FWD)% is 3.36%.
How many employees does Ono Pharmaceutical have?▼
As of November 22, 2026, the company has 4,206 employees.
In which sector is Ono Pharmaceutical located?▼
Ono Pharmaceutical operates in the Health & Wellness sector.
When did Ono Pharmaceutical complete a stock split?▼
The last stock split for Ono Pharmaceutical was on April 4, 2016 with a ratio of 3:1.
Where is Ono Pharmaceutical headquartered?▼
Ono Pharmaceutical is headquartered in Osaka, Japan.